Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Feb 2018
At a glance
- Drugs Buparlisib (Primary) ; Panitumumab
- Indications Colorectal cancer
- Focus Adverse reactions
- 30 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 14 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated